

Attorney Docket: 26230 Date: January **20**, 2006

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Art Unit: 1615

DIETRICH, et al.

Examiner: Silverman, E.

Serial No.:

10/505,138

Filed:

August 19, 2004

Title:

ORAL DOSAGE FORM CONTAINING A PDE 4 INHIBITOR AS A ACTIVE

INGREDIENT AND POLYVINYLPYRROLIDON AS EXCIPIENT

#### TRANSMITTAL LETTER

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith for filing in the U.S. Patent and Trademark Office is the following:

- 1) Information Disclosure Statement;
- 2) PTO Form-1449 with 1 cited Reference;
- 3) Copy of the 1 cited Reference;
- 4) Check No. 1564 in the amount of \$ 180.00, for submission of an Information Disclosure Statement fee, required by 37 C.F.R. 1.17(p).

The Commissioner is hereby authorized to charge any deficiency or credit any excess to Deposit Account No. 14-0112.

Respectfully submitted, NATH & ASSOCIATES PLLC

Gary M. Nath, Reg. No. 26,965

Sheldon M McGee, Reg. No. 50,454

Customer No. 34375

NATH & ASSOCIATES PLLC 112 South West Street Alexandria, VA 22314 GMN/SMM/le (AfterAction.IDS.34375) PE 4030 NOTE TO THE TOTAL PROPERTY OF THE TRANSPORTER THE TRANSPORTER TO THE TOTAL PROPERTY OF THE TOTAL PROPE

Attorney Docket: 26230 Date: January **20**, 2006

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Art Unit: 1615

DIETRICH, et al. Examiner: Silverman, E.

Serial No.: 10/505,138

Filed: August 19, 2004

Title: ORAL DOSAGE FORM CONTAINING A PDE 4 INHIBITOR AS A ACTIVE INGREDIENT AND POLYVINYLPYRROLIDON AS EXCIPIENT

## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

#### Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

- [ ] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- [XXX] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed statement is accompanied by [check one]:

- [] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or
- [X] ii. a check in the amount<sup>01</sup>经领性控制 b 例明新 6 5551 段。 1.17(p). 01 FC:1886 180.80 OP
- [ ] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.

Attorney Docket: 26230 Serial No.: 10/505,138 Page 2

[	]	C€	ertific	cat	ion i	report(e	e) k	pelow; a	nd		
[	]	а	check	in	the	amount	as	require	d by	1.17(p)	)

- [ ] d. The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.
- [ ] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]
  - I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

- [ ] Appropriate certification is attached.
- [XXX] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.
- [XXX] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

Attorney Docket: 26230 Serial No.: 10/505,138 Page 3

[ ] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

## and / or

[ ] Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted, NATH & ASSOCIATES PLLC

Gary M. Nath, Reg. No. 26,965 Sheldon M. McGee, Reg. No. 50,454

Customer No. 34375

NATH & ASSOCIATES PLLC 112 South West Street Alexandria, VA 22314 GMN/SMM/le (AfterAction.IDS.Statement.34375)

Page **1** of

Attorney Docket: 26230 In re Application of: Art Unit: DIETRICH, et al. 1615 FORM PTO-1449 Serial No: Filed: Examiner: 10/505,138 August 19, 2004 Silverman, INFORMATION DISCLOSURE CITATION U.S. PATENT DOCUMENTS Examiner Issue / Initial Document Number Publication Date Inventor Filed A1 A2 A3 FOREIGN PATENT DOCUMENTS Document Number Publication Date Translation Country A4 A5 Α6 A7 8A OTHER (Including Author, Title, Date, Pertinent Pages, etc.) Bühler, V., "Polyvinylpyrrolidone for the Pharmaceutical A9 Industry", Kollidon-BASF, 2ed., Pages 1-287, (1995). A10 A11 A12 A13 A14 Examiner Date Considered EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609. Draw line through citation if not in conformance and not considered. Include

copy of this form with next communication to Applicant.